The Readout Loud

The Readout Loud

Por: STAT
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
386 episodios disponibles

Latest episodes of the podcast The Readout Loud

Mostrando página 5 de 20

304: Controversial brain tissue research, obesity drug sales and Novartis’ M&A drama 02/05/2024
303: A new obesity startup, an acquisition gone wrong, & the future of Teledoc 18/04/2024
302: Vertex's big deal, biotech's red numbers, & an industry history lesson 11/04/2024
301: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise 04/04/2024
300: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech 28/03/2024
299: Live! From the STAT Breakthrough Summit East 21/03/2024
298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard 14/03/2024
297: VC turmoil, GLP-1 competition, & the war on recovery 07/03/2024
296: Legal insider trading, booming biotech stocks, & the next GLP-1 29/02/2024
295: Humira’s legacy, CEO symbolism, and genomic surgery 22/02/2024
294: Pharma goes to Washington, Alnylam's future, & Gilead's dealmaking 15/02/2024
293: AI in medicine, detangling hype, and Icelandic DNA 08/02/2024
292: Vertex's polarizing data, Aduhelm's adieu, & an FDA icon 01/02/2024
291: The plight of the VC, Gilead's latest setback, & more M&A 25/01/2024
290: Biotech layoffs, slumping stocks, and a 2024 preview 18/01/2024
289: Live! From #JPM24 11/01/2024
287: 2023 in review, CEO report cards, and a look at the year ahead 21/12/2023
286: FTC v. biotech, Pfizer's kitchen sink, & Vertex's future 14/12/2023
285: CRISPR history, biotech struggles, & a big week for deals 07/12/2023
284: AbbVie’s big deal, CAR-T’s risks, & getting a biotech job 30/11/2023
« Primera ‹ Anterior 1 ... 3 4 5 6 7 ... 20 Siguiente › Última »
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA